mavacamten
Camzyos · ATC code C01EB
- Key facts
- Active substance
- mavacamten
- ATC code
- C01EB
- Authorisation
- centrally authorised across the EU (EMA)
- Dosage forms
- CAMZYOS 2.5 mg hard capsules / CAMZYOS 5 mg hard capsules / CAMZYOS 10 mg hard capsules
- Marketing authorisation holder
- Bristol-Myers Squibb Pharma EEIG
- Information as of
- 2026-10-27
Key facts
Mavacamten is a selective allosteric inhibitor of cardiac myosin. It is used to treat symptomatic obstructive hypertrophic cardiomyopathy in adults.
What it is used for
- Symptomatic (NYHA class II-III) obstructive hypertrophic cardiomyopathy in adults
Dosing
- Before starting: assess LVEF by echocardiography (do not start if LVEF < 55%), pregnancy test in women of childbearing potential, CYP2C19 genotyping
- CYP2C19 poor metabolisers: starting dose 2.5 mg once daily, maximum 5 mg
- Intermediate, normal, rapid and ultra-rapid metabolisers: starting dose 5 mg once daily, maximum 15 mg
- Until the phenotype is known, poor-metaboliser dosing instructions apply
- Dose adjustments based on LVOT gradient and LVEF follow the scheme in the full text
Contraindications
- Hypersensitivity to the active substance or excipients
- Pregnancy and women of childbearing potential not using effective contraception
- Strong CYP3A4 inhibitors in CYP2C19 poor metabolisers or undetermined phenotype
- Combination of a strong CYP2C19 inhibitor and a strong CYP3A4 inhibitor
Important warnings
- Reduces LVEF and may cause heart failure due to systolic dysfunction; monitor LVEF closely and interrupt treatment if needed
- Greater risk with serious intercurrent illness (infection, arrhythmia such as atrial fibrillation) or major cardiac surgery
- New or worsening dyspnoea, chest pain, fatigue, palpitations, leg oedema or rising NT-proBNP should prompt evaluation
- Interactions via CYP2C19/CYP3A4 can cause heart failure or loss of response
Side effects
- Most common: dizziness, dyspnoea, systolic dysfunction and syncope
Interactions
- CYP2C19 and CYP3A4 inhibitors or inducers change mavacamten levels depending on CYP2C19 phenotype
- Starting or increasing a negative inotrope: close medical supervision with LVEF monitoring
Pregnancy and breastfeeding
- Contraindicated in pregnancy; effective contraception during treatment and for 6 months after stopping
- Women must not breast-feed during treatment
Summary of the official product information, written with AI (Claude, Anthropic) on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.
Common questions – ask Medelix
For patients
Package leaflet, verbatim
Authorisation and brand names by country
Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.
EU – centrally authorised (all member states)
- CamzyosBristol-Myers Squibb Pharma EEIG · EMEA/H/C/005457
Source: European Medicines Agency (EMA), product information
Brand names in 3 more European countries
- Iceland
- Camzyos
- Liechtenstein
- Camzyos
- Norway
- Camzyos
EMA – Article 57 product data (EU/EEA), 2026-10-28
Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.
Other substances in the same group
Another question about this substance?
Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.
Sources
- European Medicines Agency. Camzyos – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/camzyos-epar-product-information_en.pdf
Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error
Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.